A phase I clinical trial study on CCL2 antibody neutralization in rheumatoid arthritis patients showed that antibody bound CCL2 complexes were still biologically active and that CCL2 levels were increased in patients [25]. This evidence concerns the gene CCL2 and rheumatoid arthritis.